ANDREW EBNER: Open Payments
NPI 1225709280 · SENECA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,573 in 75 payments from 14 companies in 2025. Trend: 2023 $442 · 2024 $580 · 2025 $1,573
Food & beverage: $1,462Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $345 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $241 |
| Alkermes, Inc. | 9 | $172 |
| E.R. Squibb & Sons, L.L.C. | 7 | $153 |
| ABBVIE INC. | 11 | $136 |
| Neurocrine BioSciences, Inc. | 6 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $122 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Janssen Pharmaceuticals, Inc | 3 | $74 |
| Noven Therapeutics, LLC | 2 | $38 |
Products named: CAPLYTA, UZEDY, COBENFY, VRAYLAR, INGREZZA, ARISTADA, REXULTI, HETLIOZ.
Industry payments across SC — which companies pay providers there.
